Baebies announced FDA 510(k) clearance and a CLIA waiver for a triplex respiratory molecular test on its Finder point-of-care platform. The assay distinguishes influenza A, influenza B, and SARS-CoV-2 from respiratory samples and is supported by ultra-rapid qPCR inside business-card-size cartridges. The company positioned Finder as the first multifunctional point-of-care instrument combining cleared molecular testing with another cleared modality, following prior clears for a clinical chemistry test and later addition of coagulation with breakthrough device designation. Baebies said its cartridge design uses spatial thermal cycling and droplet shuttling between temperature and detection zones, enabling higher multiplexing—already demonstrated at 48 targets, with more theoretically possible. The update is notable for biotech diagnostics because it expands the clinical utility of multiplex respiratory testing in near-patient settings while reinforcing the trend toward integrating multiple assay types into single workflows to reduce turnaround time and operational burden.